YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - SCYNEXIS, Inc. (SCYX), a clinical-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, swinging to a net profit compared to a loss last year. In addition, the company provided an u…
* SCYNEXIS press release [https://seekingalpha.com/pr/20613730-scynexis-reports-second-quarter-2026-financial-results-and-provides-corporate-update] (SCYX [https://seekingalpha.com/symbol/SCYX]): Q2 GAAP EPS of $0.63 beats by $1.14. * Reve…
Scynexis JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-…
JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for A…
(RTTNews) - Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million. The deal includes an upfront pa…
SCYNEXIS, Inc. (NASDAQ:SCYX) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy On February 26, 2026, SCYNEXIS, Inc. (NASDAQ…
(RTTNews) - SCYNEXIS, Inc. (SCYX) has reported its full-year 2025 results, while highlighting progress across its antifungal pipeline, including its next-generation candidate SCY-247 and updates on its partnership with GSK for BREXAFEMME.…
CERo Therapeutics Holdings, Inc. SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company pursuing new targets and…
Scynexis JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced…
Scynexis GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid sing…
GSK remains committed to the relaunch of BREXAFEMME, and following its relaunch, SCYNEXIS stands to receive up to $145.5 million in annual net sales milestones as well as royalties, net of payments to Merck, in the low to mid single digit…
Five-year grant of $7 million annually to the academic researchers is aimed at accelerating the development of new therapeutics to combat resistant fungal infections, including the Company’s next generation of triterpenoid antifungals (fun…
SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s request to terminate t…
(RTTNews) - Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several na…
Scynexis SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the MARIO study The payment from GSK, com…
SCYNEXIS to receive a $22 million payment as part of the resolution related to the restart of the Phase 3 MARIO study on invasive candidiasis Scynexis will promptly wind-down and terminate the MARIO study The payment from GSK, combined wit…
(RTTNews) - SCYNEXIS (SCYX), Tuesday reported positive Phase 1 results for its next-generation triterpenoid antifungal for invasive fungal infections, SCY-247. SCY-247 was well tolerated, with only mild to moderate adverse events reported…
Oral presentation will feature data demonstrating SCY-247 in vitro activity against C. auris strains, including isolates with mutations commonly associated with echinocandin-resistanceAdditional poster presentations highlight SCY-247’s bro…
* SCYNEXIS press release [https://seekingalpha.com/pr/20200280-scynexis-reports-second-quarter-2025-financial-results-and-provides-corporate-update] (NASDAQ:SCYX [https://seekingalpha.com/symbol/SCYX]): Q2 GAAP EPS of -$0.14 beats by $0.05…
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient d…
SCYNEXIS, Inc. (NASDAQ:SCYX) has officially restarted patient dosing in its Phase III MARIO trial for Brexafemme (ibrexafungerp) after the FDA lifted a nearly two-year clinical hold. The hold, initiated over concerns of beta-lactam contami…
First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold Resumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously…
Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme. Hansoh recently received Chinese (NM…
The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025. Four presentations for SCY-247 were accepted by the European Society of Clinical M…
Investing in small-cap stocks can be a gateway to high returns, mainly when these companies exhibit strong growth fundamentals and strategic market positioning. Here, the focus is on three stocks to buy under $10. The fundamentals behind t…
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That’s because the world of drug development and biotech research tends to rely on big market-mo…
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price. Of course, the broader healthcare ecosystem offers a compellin…
In this article, we will take a detailed look at the 14 Cheap Penny Stocks to Buy According to Analysts. For a quick overview of such stocks, read our article5 Cheap Penny Stocks to Buy According to Analysts. The US stock market is going t…
LOS ANGELES, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
NEW YORK, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”)…
BENSALEM, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the dea…
LOS ANGELES, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 8, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or…
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (the…
In this piece, we will take a look at the 11 cheapest stocks with the biggest upside. If you want to skip our introduction to stock valuation and recent market news, then take a look at 5 Cheapest Stocks With Biggest Upside. Identifying th…
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against SCYNEXIS, Inc. (“SCYNEXIS” or the “Company”)…
NEW YORK, Nov. 24, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (the…